Quality of Life Related to Functional Disability in Migraine Patients: A Systematic Review and Network Meta-analysis
Discussion:
For short-term prevention of migraine, fremanezumab demonstrated slightly better improvement in disability compared with other anti-calcitonin gene-related peptide monoclonal antibodies in adult patients with migraine.
Source: The Clinical Journal of Pain - Category: Anesthesiology Tags: Review Articles Source Type: research
More News: Anesthesiology | Chronic Pain | Clinical Trials | Disability | Genetics | Headache | Migraine | Pain | Study